180 related articles for article (PubMed ID: 35191952)
1. PARK2 regulates eIF4B-driven lymphomagenesis.
Kapadia BB; Roychowdhury A; Kayastha F; Nanaji N; Gartenhaus RB
Mol Cancer Res; 2022 Feb; 20(5):735-48. PubMed ID: 35191952
[TBL] [Abstract][Full Text] [Related]
2. PARK2 regulates eIF4B-driven lymphomagenesis.
Kapadia BB; Roychowdhury A; Kayastha F; Nanaji N; Gartenhaus RB
Mol Cancer Res; 2022 Feb; ():. PubMed ID: 35105670
[TBL] [Abstract][Full Text] [Related]
3. Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.
Kapadia B; Nanaji NM; Bhalla K; Bhandary B; Lapidus R; Beheshti A; Evens AM; Gartenhaus RB
Nat Commun; 2018 Feb; 9(1):829. PubMed ID: 29483509
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X
Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938
[No Abstract] [Full Text] [Related]
5. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
6. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
7. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B.
van Gorp AG; van der Vos KE; Brenkman AB; Bremer A; van den Broek N; Zwartkruis F; Hershey JW; Burgering BM; Calkhoven CF; Coffer PJ
Oncogene; 2009 Jan; 28(1):95-106. PubMed ID: 18836482
[TBL] [Abstract][Full Text] [Related]
8. ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
Davies A; Barrans S; Burton C; Mercer K; Caddy J; Chinnery F; Day L; Fernando D; Ardeshna K; Collins G; Radford J; Rule S; McMillan A; Johnson P; Griffiths G
F1000Res; 2020; 9():941. PubMed ID: 33093947
[No Abstract] [Full Text] [Related]
9. Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Lin DC; Xu L; Chen Y; Yan H; Hazawa M; Doan N; Said JW; Ding LW; Liu LZ; Yang H; Yu S; Kahn M; Yin D; Koeffler HP
Cancer Res; 2015 May; 75(9):1815-27. PubMed ID: 25877876
[TBL] [Abstract][Full Text] [Related]
10. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
[TBL] [Abstract][Full Text] [Related]
12. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
Wang Y; Begley M; Li Q; Huang HT; Lako A; Eck MJ; Gray NS; Mitchison TJ; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9810-5. PubMed ID: 27528663
[TBL] [Abstract][Full Text] [Related]
13. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
14. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
15. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways.
Shahbazian D; Parsyan A; Petroulakis E; Hershey J; Sonenberg N
Cell Cycle; 2010 Oct; 9(20):4106-9. PubMed ID: 20948310
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
18. Influenza A virus-induced degradation of eukaryotic translation initiation factor 4B contributes to viral replication by suppressing IFITM3 protein expression.
Wang S; Chi X; Wei H; Chen Y; Chen Z; Huang S; Chen JL
J Virol; 2014 Aug; 88(15):8375-85. PubMed ID: 24829357
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
20. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
